Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0O2WJ
|
|||
| Drug Name |
Losartan
|
|||
| Synonyms |
Cozaar; Cozaar (TN); DUP 89; DuP 753; DuP-753; Hyzaar; JMS50MPO89; LOSARTAN POTASSIUM; Lortaan; Losartan (INN); 114798-26-4; C22H23ClN6O; CHEBI:6541; CL23623; Losartan [INN:BAN]; Losartan monopotassium salt; Losartic; Losartic (TN); MK-954; MK954; UNII-JMS50MPO89; [3H]losartan
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Approved | [1] | |
| Coronavirus Disease 2019 (COVID-19) [ICD-11: 1D6Y] | Phase 3 | [2], [3] | ||
| Therapeutic Class |
Antiviral Agents
|
|||
| Company |
Merck & Co
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H23ClN6O
|
|||
| Canonical SMILES |
CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
|
|||
| InChI |
1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)
|
|||
| InChIKey |
PSIFNNKUMBGKDQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 114798-26-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9283, 842088, 4964191, 6595486, 7979808, 8152487, 11364607, 11367169, 11369731, 11372014, 11374749, 11377893, 11485629, 11489493, 11490813, 11492940, 11495527, 14758375, 14880416, 26612696, 26680690, 26748956, 26748957, 29223075, 46506538, 46530544, 47773674, 48072880, 48221855, 48416186, 49979780, 50107496, 50150720, 53789286, 56312013, 56314181, 57322070, 85209145, 85789659, 91011664, 92124757, 92307932, 93166444, 93617630, 96024836, 99375910, 103546496, 104086517, 104305027, 118212888
|
|||
| ChEBI ID |
CHEBI:6541
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | HUMAN type-1 angiotensin II receptor (AGTR1) | Target Info | Blocker | [4], [5] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 2 | ClinicalTrials.gov (NCT04343001) Coronavirus Response - Active Support for Hospitalised Covid-19 Patients. U.S. National Institutes of Health. | |||
| REF 3 | Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease: A Viewpoint on the Potential Influence of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers on Onset and Severity of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. J Am Heart Assoc. 2020 Apr 7;9(7):e016219. | |||
| REF 4 | Controversies of renin-angiotensin system inhibition during the COVID-19 pandemic. Nat Rev Nephrol. 2020 Apr 3. | |||
| REF 5 | FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 020386 | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.